UK markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.6400+0.0300 (+1.15%)
As of 03:14PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 466.09M
Enterprise value 615.39M
Trailing P/E N/A
Forward P/E 1.04
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.36
Price/book (mrq)74.89
Enterprise value/revenue 5.98
Enterprise value/EBITDA -4.11

Trading information

Stock price history

Beta (5Y monthly) 0.78
52-week change 3-55.23%
S&P500 52-week change 324.16%
52-week high 36.7500
52-week low 30.7000
50-day moving average 32.3712
200-day moving average 31.5769

Share statistics

Avg vol (3-month) 36.3M
Avg vol (10-day) 34.09M
Shares outstanding 5178.92M
Implied shares outstanding 6178.92M
Float 8113.17M
% held by insiders 10.27%
% held by institutions 143.19%
Shares short (31 Jan 2024) 420.07M
Short ratio (31 Jan 2024) 42.52
Short % of float (31 Jan 2024) 412.58%
Short % of shares outstanding (31 Jan 2024) 411.22%
Shares short (prior month 29 Dec 2023) 419.92M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin -202.51%
Operating margin (ttm)-81.05%

Management effectiveness

Return on assets (ttm)-36.44%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)102.9M
Revenue per share (ttm)1.10
Quarterly revenue growth (yoy)79.00%
Gross profit (ttm)N/A
EBITDA -155.46M
Net income avi to common (ttm)-208.39M
Diluted EPS (ttm)-2.2700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)114.83M
Total cash per share (mrq)1.01
Total debt (mrq)531.53M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.59
Book value per share (mrq)-3.66

Cash flow statement

Operating cash flow (ttm)-140.9M
Levered free cash flow (ttm)-113.74M